13.05

0.53% -0.07

After Hours: 13.23 0.18 +1.38%

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $13.05, with a volume of 1.35M. It is down -0.53% in the last 24 hours and up +10.31% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$13.12

Open:

$13.1

24h Volume:

1.35M

Relative Volume:

0.54

Market Cap:

$4.16B

Revenue:

$3.02B

Net Income/Loss:

$127.93M

P/E Ratio:

58.97

EPS:

0.2213

Net Cash Flow:

$225.64M

1W Performance:

+2.68%

1M Performance:

+10.31%

6M Performance:

+33.44%

1Y Performance:

+82.01%

1-Day Range:

$12.90

$13.18

1-Week Range:

$12.30

$13.22

52-Week Range:

$7.01

$15.42

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2026-02-27

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	13.05	4.19B	3.02B	127.93M	225.64M	0.2213
TAK Takeda Pharmaceutical Co Adr	17.85	56.39B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	120.76	50.93B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.66	43.19B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.61	36.99B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	577.58	25.36B	3.18B	1.33B	1.04B	27.90

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Jun-06-25	Initiated	Goldman	Buy
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

09:16 AM

Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. - GlobeNewswire

Apr 14, 2026

Amneal launches generic bimatoprost 0.01% to US market - Eyes On Eyecare

Apr 14, 2026

Apr 13, 2026

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced the official launch of Albuterol Sulfate and Beclomethasone Dipropionate HFA inhalation aerosols in the U.S. market. - Bitget

Apr 13, 2026

Institution Moves: Is Amneal Pharmaceuticals Inc a strong candidate for buy and hold2026 Price Momentum & Low Risk High Reward Ideas - baoquankhu1.vn

Apr 13, 2026

Aug Fed Impact: Is Amneal Pharmaceuticals Inc in a long term uptrend2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Should Amneal’s New Generic Glaucoma Launch Shape How AMRX Investors View Its Specialty Strategy? - Sahm

Apr 12, 2026

Apr 11, 2026

Fund Flows: Is Amneal Pharmaceuticals Inc forming a double bottomEarnings Overview Summary & Fast Momentum Entry Tips - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook - qz.com

Apr 10, 2026

Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing - qz.com

Apr 10, 2026

Is AMRX Stock Undervalued? Sales Multiple, Target, Upside - qz.com

Apr 10, 2026

Why Amneal Pharmaceuticals (AMRX) is a top growth stock for the long term - MSN

Apr 10, 2026

AMRX: 3 Key Factors Fueling Amneal's Projections for 2026 - Bitget

Apr 10, 2026

Here's the way AMRX is leveraging the demand for GLP-1 via its manufacturing operations - Bitget

Apr 10, 2026

Why Amneal Pharmaceuticals (AMRX) Stands Out as a Leading Long-Term Growth Stock - Bitget

Apr 10, 2026

FOCUS-Patients scramble to find estrogen patches as shortage worsens after US FDA champions use - Sahm

Apr 10, 2026

Is It Time To Reassess Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Share Price Run? - Sahm

Apr 10, 2026

Apr 09, 2026

A Look At Amneal Pharmaceuticals (AMRX) Valuation After Launching Its New Glaucoma Generic - Yahoo Finance

Apr 09, 2026

FDA sends latest Untitled Letters to Amneal, BioCorRx over brochures, websites - Medical Marketing and Media

Apr 09, 2026

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% - Bitget

Apr 09, 2026

Apr 08, 2026

AMRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Volatility Watch: Whats the fair value of Amneal Pharmaceuticals Inc stock2026 Historical Comparison & Proven Capital Preservation Tips - baoquankhu1.vn

Apr 08, 2026

Amneal marks Parkinson's Awareness Month, $2M donation - Post Register

Apr 08, 2026

Apr 07, 2026

Amneal to Report First Quarter 2026 Results on May 1, 2026 - The Manila Times

Apr 07, 2026

Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month - The Manila Times

Apr 07, 2026

$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan

Apr 07, 2026

Apr 06, 2026

Trading Recap: Whats the fair value of Amneal Pharmaceuticals Inc stockRate Cut & Low Volatility Stock Recommendations - baoquankhu1.vn

Apr 06, 2026

Apr 05, 2026

Allspring Global Investments Holdings LLC Grows Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat

Apr 05, 2026

Apr 04, 2026

Pharma News: Is Amneal Pharmaceuticals Inc in a long term uptrend2026 Geopolitical Influence & Technical Pattern Recognition Alerts - baoquankhu1.vn

Apr 04, 2026

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Apr 04, 2026

Apr 02, 2026

Amneal Pharmaceuticals Stock: Generic Drug Leader Faces Recall Challenges Amid Sector Growth Opportu - AD HOC NEWS

Apr 02, 2026

Mar 31, 2026

Tudor Investment Corp ET AL Takes Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat

Mar 31, 2026

JPMorgan Chase & Co. Has $7.72 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat

Mar 31, 2026

Mar 30, 2026